医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders

2018年09月28日 PM03:10
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Further to the announcement of the recommended acquisition of Shire plc (“Shire”) on May 8, 2018 (“the Acquisition”), Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda” or the “Company”) today announced that the Company has established the record date for the Extraordinary General Meeting of Shareholders, to vote on the necessary matters relating to the proposed Acquisition as follows.

Record Date Regarding the Extraordinary General Meeting of Shareholders

Takeda has set October 19, 2018 as the record date. Shareholders recorded in the final shareholder registry on that date shall be entitled to exercise voting rights at the Extraordinary General Meeting of Shareholders. Establishment of an October 19, 2018 record date gives the company the discretion to hold the Extraordinary General Meeting of Shareholders within the three month period ending January 18, 2019. If the company does not decide to hold the Extraordinary General Meeting of Shareholders on any date falling within the three month period ending January 18, 2019, a new record date will be established and announced.

1.       Record date:             October 19, 2018
2. Date of public notice: October 1, 2018
3. Method of public notice:

The relevant information will be posted on the Takeda website by an
electronic public notice (Japanese only).

Significant Progress To-Date

Since the announcement of the recommended offer on May 8, 2018, Takeda has successfully completed several significant milestones in the Acquisition process, including:

  • Entering into a USD 7.5 billion term loan credit agreement with leading global financial institutions.
  • Confirming a post-closing focus on key therapeutic areas including gastroenterology, oncology, neuroscience and rare diseases as well as vaccines and plasma-derived therapies.
  • Developing a future operating model as part of planning efforts to facilitate the successful integration of Takeda and Shire following completion of the Acquisition. Takeda is planning to implement a lean post-closing organizational structure with clearly-defined accountabilities and ownership. The future operating model is intended to further strengthen Takeda’s patient- and customer-centric organization.
  • Receipt of unconditional clearance from regulatory agencies in a number of key jurisdictions, including the United States Federal Trade Commission, the Brazilian Administrative Council for Economic Defense and the State Administration for Market Regulation in China, among other regulatory authorities.

The Acquisition will create a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. It will strengthen Takeda’s presence in the United States, an important and growing market, will reinforce our pipeline, and provide cash flow to continue to invest in our R&D engine while creating a more competitive, agile and highly profitable company.

The significantly strengthened cash flow generation which the Acquisition is expected to provide will support the maintenance of Takeda’s well-established dividend policy and facilitate rapid de-leveraging to a net debt to EBITDA ratio of 2.0x or less within three to five years following closing of the Acquisition. To help accelerate the de-leveraging process and ensure an optimal business mix, Takeda may consider selected divestitures of non-core businesses.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.

For more information, visit https://www.takeda.com/newsroom/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180927006041/en/

CONTACT

Takeda (Investor Relations)
Takashi Okubo, +81 3 3278 2306
takeda.ir.contact@takeda.com
or
Takeda
(Media – outside Japan)

Elissa Johnsen, +1 312 285 3203
Elissa.Johnsen@takeda.com
or
Takeda
(Media – within Japan)

Kazumi Kobayashi, +81 3 3278 2095
Kazumi.Kobayashi@takeda.com
or
Tsuyoshi
Tada, +81 3 3278 2417
Tsuyoshi.Tada@takeda.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CDISC and Cohen Veterans Bioscience Announce Release of First Data Standard to Improve Research for Post Traumatic Stress Disorder
  • 武田薬品とニューヨーク科学アカデミーによる”2019 Innovators in Science Award”の受賞者発表について
  • Takeda and the New York Academy of Sciences Announce 2019 Innovators in Science Award Winners
  • Vitruvias Therapeutics Inc.授权保瑞药业台湾竹南厂区生产ANDA氯化钾缓释(10和20毫当量)片剂
  • 中国の尚湖が国際健康展示区へと発展